A closer look at “New Drug Launch Prices Jump 35% Since 2022 Despite Discounts”, exactly as the source publishes it. The median net price for newly launched medicines in the U.S. climbed 35% between 2022 and 2025, even after adjusting for inflation and manufacturer discounts, according to a new analysis. That sharp increase highlights a persistent trend: pharmaceutical companies are setting higher list prices at launch, and even with rebates and concessions, the actual amount paid by insurers and patients is rising faster than the broader economy.
The finding matters because launch prices set the baseline for a drug's entire commercial life, influencing patient out-of-pocket costs, insurer formulary decisions, and federal spending through programs like Medicare. While manufacturers often argue that net prices reflect significant rebates, this data suggests those discounts are not enough to offset aggressive launch pricing. The full version stays on the original page, which this listing opens directly.